Sodium borohydride → HCID 57805586, compound
Reaction equation
[Cl:1][C:2]1[C:3]([C:26]([F:29])([F:28])[F:27])=[N:4][N:5]([CH2:8][C:9]([N:11]2[CH2:16][CH2:15][C:14]([C:19]3[CH:24]=[CH:23][C:22]([Cl:25])=[CH:21][CH:20]=3)([C:17]#[N:18])[CH2:13][CH2:12]2)=[O:10])[C:6]=1[CH3:7].[BH4-].[Na+]>[Co](Cl)Cl.CO>[NH2:18][CH2:17][C:14]1([C:19]2[CH:24]=[CH:23][C:22]([Cl:25])=[CH:21][CH:20]=2)[CH2:13][CH2:12][N:11]([C:9](=[O:10])[CH2:8][N:5]2[C:6]([CH3:7])=[C:2]([Cl:1])[C:3]([C:26]([F:27])([F:29])[F:28])=[N:4]2)[CH2:16][CH2:15]1Participants
5
Reactant 2
Product 1
Reagents, catalysts & solvents 2
Procedure
In a 4 mL vial was added 50 mg of 1-[2-(4-chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-4-(4-chloro-phenyl)-piperidine-4-carbonitrile (0.11 mmol, 1.00 eq), 80 mg cobalt (II) chloride (0.33 mmol, 3.00 eq), 10 mg NaBH4 (0.22 mmol, 2.00 eq) and 500 uL methanol. The mixture was allowed to stir overnight at room temperature and the crude product was purified by reversed phase HPLC (acetonitrile—H2O with 0.1% TFA as the eluent) to yield 1-[4-aminomethyl-4-(4-chloro-phenyl)-piperidin-1-yl]-2-(4-chloro-5-methyl-3-trifluoromethyl-pyrazol-1-yl)-ethanone. MS (ES) M+H expected=448.0, found=448.1
Workup
- customthe crude product was purified by reversed phase HPLC (acetonitrile—H2O with 0.1% TFA as the eluent)
Sources & evidence
- ORD record
- ord-55c4268831524474afeb27c3e384ea29
- Source dataset
- uspto-grants-2009_08
- Patent number
- US07576218B2
Reaction notes
Loading…